Delving into the Latest Updates on AKST-1220 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

LTA4H

Action

inhibitors

Mechanism

LTA4H inhibitors(Leukotriene A-4 hydrolase inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Alzheimer Diseasedisorder of aging

Inactive Indication-

Originator Organization

Alkahest, Inc.Startup

Active Organization

Alkahest, Inc.Startup

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC21H23NO4

InChIKeyMUKBVXXQQUJGNF-HXUWFJFHSA-N

CAS Registry1400796-47-5

Leukotrienes, a class of inflammatory bioactive lipids, are well studied in the periphery, but less is known of their importance in the brain. We identified that the enzyme leukotriene A4 hydrolase (LTA4H) is expressed in healthy mouse neurons, and inhibition of LTA4H in aged mice improves hippocampal dependent memory. Single-cell nuclear RNA sequencing of hippocampal neurons after inhibition reveals major changes to genes important for synaptic organization, structure, and activity. We propose that LTA4H inhibition may act to improve cognition by directly inhibiting the enzymatic activity in neurons, leading to improved synaptic function. In addition, LTA4H plasma levels are increased in both aging and Alzheimer’s disease and correlated with cognitive impairment. These results identify a role for LTA4H in the brain, and we propose that LTA4H inhibition may be a promising therapeutic strategy to treat cognitive decline in aging related diseases.

100 Deals associated with AKST-1220

Login to view more data